<DOC>
	<DOC>NCT00749879</DOC>
	<brief_summary>This study is intended to evaluate the pharmacokinetic properties of two doses (25 mg and 50 mg) of Proellex® formulated with microcrystalline cellulose (MCC) from 2 different suppliers in the fed and fasting states.</brief_summary>
	<brief_title>Crossover Study of the Safety and PK Properties of Proellex®</brief_title>
	<detailed_description />
	<criteria>Subject must be able to speak, read, and understand English and be willing and able to provide written informed consent in English on an Institutional Review Board (IRB) Premenopausal women aged 1834, inclusive, with body mass index between 18 and 35, inclusive Women of childbearing potential must be willing to use effective nonhormonal, doublebarrier method contraception during the study period and for a minimum of 30 days after discontinuation of the study medication. Women who have had a hysterectomy will be allowed into the study Must have a negative urine pregnancy test at screening Able to swallow gelatin capsules Medically normal subjects with no significant abnormal findings at the screening physical examination as evaluated by the Principal Investigator that would interfere with the subject participating this study Must have agreed to not attempt to become pregnant at any time during study participation or for 30 days thereafter Other inclusion criteria may apply Symptomatic uterine fibroids or endometriosis Past or present history of any significant cardiovascular, renal, or hepatic disease requiring ongoing medical therapy or clinical intervention Past or present history of thrombophlebitis, thromboembolic disorders, or cerebrovascular accident Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Principal Investigator Significant organ abnormality or disease (based on the Principal Investigator's judgment) that would in the opinion of the Principal Investigator exclude the subject from participating Other exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PK</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>